Fibrocell Science (FCSC) Tops Q1 EPS by 6c

Fibrocell Science (NASDAQ: FCSC) reported Q1 EPS of ($0.11), $0.06 better than the analyst estimate of ($0.17).

“Our achievements in the first quarter of 2018 have set the stage for continued progress of Fibrocell’s gene therapy clinical programs that address rare conditions of the skin and connective tissue with high unmet needs,” said John Maslowski, President and Chief Executive Officer of Fibrocell. “In January, we obtained allowance from the U.S. Food and Drug Administration to enroll pediatric patients in the Phase 2 portion of our Phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa. In addition, the Phase 1 portion of this trial continued to advance and we expect to report additional interim adult data in the second quarter of 2018.”

“Furthermore, our FCX-013 program for the treatment of moderate to severe localized scleroderma made important progress. In March 2018, Fibrocell was granted allowance by the FDA of the Investigational New Drug Application for FCX-013 to proceed to clinical trials,” said Mr. Maslowski.

For earnings history and earnings-related data on Fibrocell Science (FCSC) click here.

You May Also Be Interested In